News

Thursday September 17, 2020

17 Sep 2020 – Update on Phase 2b clinical study of lead asset XF-73 in the prevent...

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Update on Phase 2b clinical study of lead asset XF-73 in the prevention of post-surgical infections Recruitment on track to complete by […]

Thursday September 17, 2020

17 Sep 2020 – Interim results for the 6 months ended 30 June 2020

Destiny Pharma today announced its interim results for the 6 months ended 30 June 2020, which can be found here.

Thursday September 10, 2020

10 Sep 2020 – Scrip article “Destiny Pharma and SporeGen back Nasal Spray ov...

To access Scrip article, please click on link below: Scrip “Destiny and SporeGen back Nasal Spray over Vaccine to tackle COVID-19”

Monday September 7, 2020

07 Sep 2020 – Destiny Pharma and SporeGen® announce collaboration and Innovate UK...

Destiny Pharma and SporeGen® announce collaboration and Innovate UK grant award to co-develop novel, preventative treatment for COVID-19 SPOR-COV™ prophylactic approach targets the innate immune system with potential to develop COVID-19 […]